Cargando…

Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study

PURPOSE: The aim of this study was to assess the safety and efficacy of microwave ablation combined with apatinib [vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor] and camrelizumab [anti-programmed death-1 (PD-1) antibody] in patients with advanced hepatocellular carcinoma (HCC). P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xin, Zhang, Qiao, Lu, Qiaorui, Cheng, Zhigang, Liu, Fangyi, Han, Zhiyu, Yu, Xiaoling, Yu, Jie, Liang, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644054/ https://www.ncbi.nlm.nih.gov/pubmed/36389778 http://dx.doi.org/10.3389/fimmu.2022.1023983

Ejemplares similares

The clinical efficacy of ultrasound-guided percutaneous microwave ablation for rib metastases with severe intractable pain: a preliminary clinical study
por: Cheng, Zhigang, et al.
Publicado: (2019)

A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
por: Yang, Qing, et al.
Publicado: (2023)

Nomogram based on albumin-bilirubin grade to predict outcome of the patients with hepatitis C virus-related hepatocellular carcinoma after microwave ablation
por: An, Chao, et al.
Publicado: (2019)

A tumor map generated from three-dimensional visualization of image fusion for the assessment of microwave ablation of hepatocellular carcinoma: a preliminary study
por: An, Chao, et al.
Publicado: (2019)

3D visualization ablation planning system assisted microwave ablation for hepatocellular carcinoma (Diameter >3): a precise clinical application
por: An, Chao, et al.
Publicado: (2020)

Microwave ablation vs. surgical resection for treatment naïve hepatocellular carcinoma within the Milan criteria: a follow-up of at least 5 years
por: Dou, Jianping, et al.
Publicado: (2022)

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
por: Ni, Jun, et al.
Publicado: (2023)

Risk factors for hemoglobinuria after ultrasonography-guided percutaneous microwave ablation for large hepatic cavernous hemangiomas
por: Liu, Fangyi, et al.
Publicado: (2018)

A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma
por: Huang, Julu, et al.
Publicado: (2023)

Cholecystectomy is associated with higher risk of recurrence after microwave ablation of hepatocellular carcinoma: a propensity score matching analysis
por: Yang, Hongcai, et al.
Publicado: (2020)

Perfluoropentane/apatinib-encapsulated metal–organic framework nanoparticles enhanced the microwave ablation of hepatocellular carcinoma
por: Zhang, Dongyun, et al.
Publicado: (2023)

Risk Factors of Ureteral Stenosis After Percutaneous Microwave Ablation of Renal Tumor, a Single-Center Experience
por: Wu, Jiapeng, et al.
Publicado: (2020)

Percutaneous Microwave Ablation Versus Open Surgical Resection for Colorectal Cancer Liver Metastasis
por: Zhao, Qinxian, et al.
Publicado: (2021)

Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
por: Ding, Xi, et al.
Publicado: (2023)

Clinical outcome of ultrasound-guided percutaneous microwave ablation on colorectal liver metastases
por: WANG, JIANBIN, et al.
Publicado: (2014)

Cause Analysis and Diagnosis and Treatment of Intestinal Fistulas After Ultrasound-Guided Microwave Ablation of Abdominopelvic Lesions
por: Tan, Shuilian, et al.
Publicado: (2021)

Does primary tumor location impact the prognosis of colorectal liver metastases patients after microwave ablation? - Lessons from 10 years’ experience
por: Zhou, Fubo, et al.
Publicado: (2017)

Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
por: Ren, Shengxiang, et al.
Publicado: (2022)

Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
por: Yuan, Guosheng, et al.
Publicado: (2020)

Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study
por: Liu, Yanfei, et al.
Publicado: (2023)

Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
por: Jing, Chao, et al.
Publicado: (2022)

Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination
por: Ju, Shuguang, et al.
Publicado: (2022)

Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
por: Lan, Chunyan, et al.
Publicado: (2020)

Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study
por: Wang, Jiaqiang, et al.
Publicado: (2021)

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
por: Xia, Yongxiang, et al.
Publicado: (2022)

Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer
por: Huang, Yahan, et al.
Publicado: (2022)

Risk Factor Analysis of Acute Kidney Injury After Microwave Ablation of Hepatocellular Carcinoma: A Retrospective Study
por: Yang, Yongfeng, et al.
Publicado: (2020)

A Machine Learning Model Based on Health Records for Predicting Recurrence After Microwave Ablation of Hepatocellular Carcinoma
por: An, Chao, et al.
Publicado: (2022)

The value of 3D visualization operative planning system in ultrasound-guided percutaneous microwave ablation for large hepatic hemangiomas: a clinical comparative study
por: Li, Xin, et al.
Publicado: (2019)

Application value of contrast‐enhanced ultrasound in preoperative localization of microwave ablation for primary hyperparathyroidism
por: Liu, Fangyi, et al.
Publicado: (2022)

Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma
por: Li, Jinpeng, et al.
Publicado: (2023)

Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer
por: Ye, Wei, et al.
Publicado: (2022)

The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers
por: Wang, Kunlun, et al.
Publicado: (2020)

Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study
por: Li, Dailong, et al.
Publicado: (2022)

Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study
por: Wu, Kunpeng, et al.
Publicado: (2023)

Ultrasound-guided percutaneous microwave ablation assisted by three-dimensional visualization operative treatment planning system and percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion for larger hepatic hilum hepatocellular (D ≥ 3 cm): preliminary results
por: Li, Xin, et al.
Publicado: (2017)

Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center
por: Ju, Shuguang, et al.
Publicado: (2022)

Hepatectomy combined with apatinib and camrelizumab for CNLC stage IIIb hepatocellular carcinoma: a phase II trial protocol
por: Huang, Jun Tao, et al.
Publicado: (2023)

Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma
por: Yang, Yonghao, et al.
Publicado: (2021)

Retracted: Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_allo9g6ndr1vbk160e28hm7a31